Search
Showing results for "Childhood interstitial lung disease "
A new Telethon Institute study has revealed a potential link between pesticide treatments in the home and a higher risk of children developing brain tumours.
A The Kids study examining drug resistance in leukaemia patients has shed new light on why some treatments may be more effective than others.
A national study led by Perth's Telethon Institute has found that folic acid supplements before and during pregnancy reduces the risk of childhood brain tumours
New research from the Telethon Institute has found that children whose father smoked at conception may have a 35% higher risk of developing leukaemia.
Dissociation is the act of separating oneself from reality and is often used by children and young people to disconnect from traumatic experiences.
Researchers in the Child Health, Development and Education Team support a number of projects financed by the World Bank and the Global Partnership for Education to promote early learning and development in Lao People’s Democratic Republic (PDR).
The ORIGINS Project has been named as a key beneficiary of the Stan Perron Charitable Foundation Research People & Platform round for 2023.
The Wal-yan Respiratory Research Centre is proud to have a team of researchers taking part in, and contributing to, the outstanding scientific programme of the European Respiratory Society International Congress, taking place in Milan.
Early intervention is being touted as the key to preventing lung damage in children with cystic fibrosis.
Rheumatic heart disease is a major cause of premature cardiovascular morbidity and mortality globally. Over the past decade, echocardiographic screening has changed our understanding of the natural history of RHD, revealing a high burden of clinically silent, mild RHD among people who cannot recall a history of preceding acute rheumatic fever. This viewpoint outlines the evidence that this earliest form of rheumatic heart disease, only detectable through echocardiographic screening, is an intermediate stage that many, but not all, individuals may pass through on the pathway to advanced rheumatic heart disease.